ABSTRACT: Idiopathic hemochromatosis is a n underdiagnosed creacable condition inherited in an a u tosomal recessive pattern. Since early treatment is of demonstrated value, screening of h igh risk groups o( individuals in a valuable exercise in prevenri •e medicine. Although examination of siblings is always recommended, the frequency of rhe hemoch romarosis gene makes the screening of children of patients with hemochro matosis an im porta nt undertak ing, as ill ustrated by the fami lies described in this report. Can J Gastroe nterol 1988;2( 4 ): 143-6
V ENESECTION EARLY IN THE COURSE
of id iopathic prima ry hemochromatosis can p reven t the iron overload which results in life th reaten ing complications in chis u nderdiagnosed d isorder (! ). [nheritancc of hemoch romatosis is autosornal recessive; it h as b een estimated that approx imate ly 10°-'o of the population in North America and Europe are heterozygous for the hemochromatosis gene, fo rmally design a rcd HFE 12.3). These two observations h ave important implications, in terms of screen ing relatives of patients to determine whether they arc homozygous fo r HFE and. therefore, have the hemoch romatosis genotype.
Screening itself is inexpensive and simple; measurement of transfcrrin saturation will accu rately identify ac least90°{, o f persons homozygous for H FE (4) (5) (6) . T he aurosomal recessive in he ritance of the con dition implies that siblings of patients are at 25'1o risk of being homozygotes themselves a nd should be screent:d. H owever, because of the h igh frequency of the HFE gene in th e general populatio n , offspring of affected individuals arc also at a considerably elevated risk of homozygosity a nd clin ical disease. Two Newfound land families which ill ustrate the value of screening offspring, as well as siblings, of hemoch romatosis patien ts are presented. PATIENTS AND M ETHODS D iagnosis: A provisional diagnosis o( hemochromatosis was maJ c with a transferrin saturauon (seru m iron/total iron bindingcapacity x !OO)greaterthan 55°., and a serum fcrr itin level greater than the 90th percentile (6). Percutaneous liver biopsic~ were performed on these individuals and h istological demonstration of pare n c h ymal iron depos ition wa s taken as confi r ming the diagn osis of h emochromatosis. H LA typ ing of affected and unaffected family members allowed the cotransmission of the H FE gene and particular HLA hap lotypcs to be followed in forni lies ( 1.7). Patie nts: The index case of fami ly I (Figure I ) was a man of 55 yea rs who presented with dark skin pigmentation and had a history o( arthritis involving hands and shoulders; he had no ch ildren. ln his sibship o f five, one sister had hemnchromatosis; she was asymptomatic. Of her six children, three were found robe affected. Of note, two of her affected sons were attending a rheumatology clinic on accoun t of arthritis but had not previously been diagnosed as having hemnch romatosis.
Faculty of
The fccted. In his sibship of eight, one brother was affected and o f this brother's offspring, seven were tested and three were found to have hemochrommosis.
In both families, liver biopsies of rho. e individuals provisionally diagno ed using iron metabolism studies revealed moderate to heavy parenchymal iron deposition in every case. In no case was any alteration of liver architecture found, nor was any excess fibrous tissue depo· sition found. 
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The sharing of HLA haplotypes by affected and unaffected family members is consistent with the cotransmission of HFE with HLA in these families. haplotypes 'marking' the HFE genes contributed by homozygous and heterozygous parents.
All affected members of each family are undergoing or have recently com· pleted a course of venesection. There· fore, each has excellent prospects of escaping long term liver injury and the Because 10% of the spouses of hcmo chromatosb paricn rs will be HFE heterozygorcs, simply by chance , it is not sur· prising chat families, such as rhose reported here , are observed in which hemochrommosis occurs in the offspring of patients. In a mating between an affected (homozygous) and a carrier (het· erozygous) individual. all offspring will necessarily receive the HFE gene from the affected (homozygous) parent and each has a 50°;, chance of receiving the HFE gene from the unaffected, hctero· zygous parent. On average, one-half of the offspring of such matings are expected to be homozygous for HFE, likely to develop clinical hemochromarosis even· tually This is illustrated by the familie~ reported here: three of six children in family I and three of seven children in family 2 are affected.
As indicated, 10":, of matings of pati· cnts a re expected to be of chis type; families showing vertical transmission of hcmochromatosis arc probably not observed more frequently s imply because the onset of hemochromatosis 1s relatively late in life. Such pseudodominant transmission of the clinical disease con fused early attempts 10 elucidate its mode of inhe ritance. C lear appreciation of recessive inheritance required the discovery chat the HFE locus is closely linked co the HLA A locus on chromosome 6 and the use of measurements of iron load to identify family members with pre symptomatic disease (9-ll in families. it should be remembered that occasional HFE hetero:ygotes may suf fer from iron overload, either by virtue of metabolic abnormality or the CC)ex1st-ence of hetcrozygotL' status and environmental factors such as alcohol abuse
The authors believe family screen mg with thr aim of presympmmatic idcnufication and treatment of persons homo-:ygLrnS for the HFE gene is a f u nda mental aspect of appropriate clmical management of hcmochromatosis. Edwards and colleagues ( 12) have demonstrated marked variability of liver iron stores in hemoch romatosis patients of similar ages and ac present 1t docs not seem possible to predict the progression of the disease in homozygotes. It seems reasonable co treat all homozygotes prophylact1cally once evidence of iron overload 1s found, venescct1on ts harmless, cffectl\'l' treatment wh ic h can he adjusted to achieYe a quannfiable clinical response ( 13 ). N iederau and co-workers ( I) demonstrated a significant reduction of life expect:mcy 111 patients whose hemochromato:,is had resulted in cirrhosis or di.1-bctes and that patients treated prior to the onset of cirrhosis had an expectation of survival indentical to that of the general population. Of particular note, hcpacocellular carcinoma, a recognized complication of hemochromacos1s, has neve r been reported in no ncirr hotic patients with hemochromatosis (I).
The pattern of association of the HFE gene with certain HLA haplocypes suggests that a small number of mutations, or perhaps a single mutation event, is responsible for this gene ( 14) . This raises the possibility that tests using oligonucleotide DNA probes could be developed, which would allow homozygotes and hetcrozygotes to be identified accurately, simply and cheaply Developing such prohcs would not be easy; this would requ ire that the HFE gene actually he found and ,cquenced At present, although the linkage of HFE to HLA on chromosome 6 1s cerum. its actual position , w1th111 at least a million base pairs. 1s not known and the gene wou ld have to he found before It could be sequenced
The fn:quency of the HI-E gene would make devclopmg oligonuclconde pmhcs worthwhile. However, even assuming the clinical impactof the H FE gene becomes hetter appreciated. as it should. the treatability ofhemochromacosis may place its molecular genetics at a lower priority than that of numerous disorders less susceptible to clinical management Abo. population screening for iron overload rather than the HFE allele has the additional hencfit of 1denufying persons with iron overload due to ocher causes, who also require diagnosis and therapy
The authors conclude that members of the families of hemochromamsis panents should be screened for iron overload. that this screenmg should mclude the child ren as well as the siblings of affected 111div1duals and that screening should be early. with the aim of preventmg iron overload and its well documented complications.
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